<DOC>
	<DOCNO>NCT02861417</DOCNO>
	<brief_summary>The goal clinical research study learn busulfan cyclophosphamide ( give helper drug list ) help control diseases list give stem cell transplant . The safety study drug combination also study .</brief_summary>
	<brief_title>Timed Sequential Busulfan Post Transplant Cyclophosphamide Allogeneic Transplantation</brief_title>
	<detailed_description>Study Groups : Participant assign 1 2 study group , depend type stem cell receive . - Group 1 receive stem cell haploidentical donor ( donor half match participant 's ) . - Group 2 receive stem cell match donor ( donor full match ) . If participant Group 1 receive busulfan , cyclophosphamide , fludarabine , tacrolimus , thiotepa , mycophenolate mofetil ( MMF ) . If participant Group 2 , receive busulfan , cyclophosphamide , fludarabine , tacrolimus . Central Venous Catheter : The chemotherapy participant receives , drug study , stem cell transplant give vein central venous catheter ( CVC ) . A CVC sterile flexible tube needle place large vein participant local anesthesia . Some blood sample also draw participant 's CVC . The CVC remain participant 's body treatment . Participant 's doctor explain procedure participant detail , require sign separate consent form . Study Drug Administration : For stem cell transplant , day participant receive stem cell call minus day . The day participant receive stem cell call Day 0 . The day participant receive stem cell call plus day . Group 1 : Participant receive busulfan vein 3 hour 2 separate day either outpatient clinic inpatient hospital . If participant receives busulfan outpatient , receive busulfan vein 3 hour Days -13 -12 . Participant admit hospital Day -8 receive fluid vein part standard care . If participant receives busulfan inpatient , admitted hospital Day -14 receive fluid vein part standard care . Participant receive busulfan vein 3 hour Days -13 -12 . Participant rest Days -11 -8 . On Day -7 , participant receive thiotepa vein 4 hour . Starting Day +5 , participant receive MMF tablet mouth 3 time day 90 day longer , doctor think participant 's best interest . Group 2 : Participant receive busulfan vein 3 hour 2 separate day either outpatient clinic inpatient hospital . If participant receives busulfan outpatient , receive busulfan vein 3 hour Days -13 -12 . Participant admit hospital Day -7 receive fluid vein part standard care . If participant receives busulfan inpatient , admitted hospital Day -14 receive fluid vein part standard care . Participant receive busulfan vein 3 hour Days -13 -12 . Participant rest Days -11 -7 . Both Groups : Both group receive : - Busulfan vein 3 hour fludarabine vein 1 hour Days -6 -3 . - On Day 0 , participant receive stem cell transplant vein . - Cyclophosphamide vein 3 hour Days +3 +4 help low risk graft-versus-host disease ( GVHD -- transplant immune tissue , stem cell , attack tissue recipient 's body ) . - Starting Day +5 , participant receive tacrolimus nonstop vein able take mouth help low risk GVHD . Participant take tacrolimus mouth 2 time day 3 month . After , participant 's tacrolimus dose may lower GVHD . Participant 's doctor discus . - Starting 1 week participant 's stem cell transplant , receive filgrastim injection skin 1 time day blood cell level return normal . Filgrastim design help growth white blood cell part participant 's standard care . Pharmacokinetic ( PK ) Testing : About 11 sample blood ( 1-2 teaspoon time ) drawn PK testing time point participant receives first dose busulfan . The study staff tell participant blood test schedule . PK test measure amount study drug body different time point help doctor decide participant 's dose busulfan Days -6 -3 . If doctor think need , PK blood test may also do Day -6 participant 's dose busulfan . A heparin lock line place participant 's vein lower number needle stick need draws . If possible PK test perform technical reason , participant take study . The study doctor discus participant . Length Study : Participant study 3 year transplant . Participant may take study early disease get bad , intolerable side effect , unable follow study direction . Participant talk study doctor want leave study early . If participant take study early , still may need return routine follow-up visit transplant , doctor think need . It may life-threatening leave study participant begin receive study drug receive stem cell . Study Tests : As part standard care , participant remain hospital 3-4 week transplant . While participant hospital , blood ( 2 teaspoon ) draw every day check side effect , routine test , check participant 's blood count , check kidney liver function , check infection . After participant send home hospital , must remain Houston area check infection transplant side effect 3 month transplant . During time , participant return clinic least 1 time week . At visit , blood ( 2 teaspoon ) draw routine test . About 1 , 3 , 6 , 12 month transplant : - Participant physical exam check symptom GVHD . - Blood ( 5 teaspoon ) draw see participant 's body react transplant . - If participant 's doctor think need , bone marrow aspiration check status disease . To collect bone marrow aspiration , area hip site numb anesthetic , small amount bone marrow withdrawn large needle . This investigational study . Busulfan , fludarabine , cyclophosphamide , filgrastim , MMF , tacrolimus , thiotepa FDA approve commercially available . It investigational give cyclophosphamide combination busulfan fludarabine stem cell transplant . Up 100 participant take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Hematologic Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>1 . Patients highrisk hematologic malignancy anticipate poor prognosis non transplant therapy , include remission induction failure treat untreated relapse . Diagnoses include ) Acute myeloid leukemia ; b ) Acute lymphocytic leukemia ; c ) Chronic myeloid leukemia ; ) Chronic lymphocytic leukemia ; e ) Myelodysplastic syndrome ; f ) Myeloproliferative syndrome ; g ) NonHodgkin 's lymphoma ; h ) Hodgkin 's Lymphoma ; ) Multiple myeloma . 2 . Patients must haploidentical related donor fully match relate unrelated donor . 3 . Ages &gt; /= 12 &lt; /= 65 year old . 4 . Performance score &gt; /= 70 Karnofsky/Lansky PS 0 1 ( ECOG &lt; /=1 ) . 5 . Left ventricular ejection fraction &gt; /= 50 % . 6 . Adequate pulmonary function FEV1 , FVC DLCO &gt; /=50 % expect corrected hemoglobin and/or volume . Children unable perform pulmonary function test ( e.g. , less 7 year old ) pulse oximetry &gt; /= 92 % room air . 7 . Creatinine clearance ( calculated creatinine clearance CockcroftGault use adjust body weight actual body weight 20 % great ideal permit ) &gt; 50 ml/min . 8 . Bilirubin &lt; /= 2 x upper limit normal ( except Gilbert 's Syndrome ) . SGPT ( ALT ) &lt; 200 . 9 . Negative Beta HCG test woman child bear potential , define postmenopausal 12 month previous surgical sterilization . Women child bear potential must willing use effective contraceptive measure study . 10 . Patient patient 's legal representative able sign inform consent . 1 . HIV seropositivity . 2 . Uncontrolled infection . 3 . Patients comorbidity score &gt; 3 . The principal investigator final arbiter eligibility comorbidity score &gt; 3 . 4 . Prior allogeneic transplant 5 . Patients active Hepatitis B C .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Other disease blood blood-forming organ</keyword>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Acute lymphocytic leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Myelodysplastic syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Myeloproliferative syndrome</keyword>
	<keyword>Non-Hodgkins lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>Hodgkins lymphoma</keyword>
	<keyword>HL</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>MM</keyword>
	<keyword>Stem cell infusion</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>Haploidentical donor</keyword>
	<keyword>Matched donor</keyword>
	<keyword>Thiotepa</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>MMF</keyword>
	<keyword>CellCept</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Mesna</keyword>
	<keyword>Mesnex</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Cytoxan</keyword>
	<keyword>Neosar</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
</DOC>